|
|
|
By Alexander K. Aust, M.S., MBA, Aust Business Solutions
Instead of automating everything — which costs a lot and doesn't solve every problem — drugmakers should focus on building scalable, need-specific supply chain operations. This article discusses supply chain resilience strategies that biotech companies can reasonably control.
|
|
|
|
Is it past time for a new approach to the COVID vaccine? Ocugen Chairman of the Board, Founder & CEO Shankar Musunuri, Ph.D. says yes, and his ideals would mark significant improvements: fewer shots, better durability, less post-vaccination transmission, and safety proven by time-tested technology.
|
|
|
Webinar
|
CAI
This webinar presents case studies from the pharma and biotech industry that show the use of digital solutions in asset performance and reliability.
|
|
Application Note
|
By Jared Clinger and William C. Barrett, Ph.D.,
W.L. Gore & Associates
We demonstrate three purification methods that provide alternative options to successfully purify a monoclonal antibody in under 30 minutes with yields greater than 95%.
|
|
Application Note
|
Entegris, Inc.
The FDA has strict requirements for magnetic bead removal prior to therapeutic use. Learn how this system effectively separates cells from microcarriers and provides maximum cell recovery.
|
|
Application Note
|
FUJIFILM Wako Chemicals U.S.A. Corp.
Extracellular vesicles (EVs) derived from mesenchymal stem cells are a promising therapeutic strategy in regenerative medicine. This app note illustrates the use of our PS affinity EVs isolation technology.
|
|
e-book
|
By Frank Agbogbo, Ph.D., Pawel Linke, Markus Neubauer, Ph.D., Brandy Sargent, Patricia McNeill, and Tim Noetzel, Ph.D.,
Roche CustomBiotech
Our expert authors explore temperature effects on product titer automated cell culture development workflows, maximizing DOE strategies, and data management.
|
|
Article
|
By Leandro Moreira,
Yourway, The Biopharma Services Company
The COVID-19 pandemic has led to the embrace across the industry of decentralized clinical trials models, but these services have also introduced novel challenges and complications.
|
|
Article
|
By Ahmed Abouzeid and David Menahem,
Sartorius
Regardless of phase, media and mixing optimization can afford operators speed and efficiency for drug processing; likewise, failing to prioritize media preparation can compromise a process.
|
|
White Paper
|
By Maysam Sodagari,
CHIRON Recombinant Proteins
Organizations developing products requiring fermentation often create custom processes from scratch, leaving room for inefficiencies, lost value, and, in the case of significant error, costly time delays.
|
|
Poster
|
By Pim Hermans, Frank Detmers, Kevin Sleijpen, Simon Adema, Hendrik Adams, Elina Klijs, Anja Overweel, Paul Janszen, Jessica de Rooij, and Laurens Sierkstra,
Thermo Fisher Scientific Bioproduction
Learn more about the CaptureSelect antibody subdomain-specific affinity resins and how they address the purification challenges in therapeutic antibody development.
|
|
Case Study
|
By Janice Abel,
Seeq Corporation
Abbott’s nutrition business manufactures a wide variety of science-based nutrition products. Here we review how the company uses Big Data and analytics to improve manufacturing productivity.
|
|
Article
|
By Jonathan M. Glynn, Ph.D.,
Pfizer CentreOne
Using a case study, the author demonstrates how comparative statistical analysis enabled his team to improve the yield of a component used in API synthesis by more than 2.5 x 108 U/batch.
|
|
Article
|
By Dr. Martin Schilling,
Evonik Corporation
Efficient drug production through cell culture depends on the complex interplay between the drug molecule, the cell, and the process. How can you balance cell growth and productivity?
|
|
Article
|
Cytiva
Embracing digital transformation, when combined with biomanufacturing best practices, supports increased productivity and efficiency in a biomanufacturing environment. Learn how distributed automation and digital plant maturity support resilient biomanufacturing.
|
|
Q&A
|
Eppendorf North America
Application scientist Dr. Jorge Escobar Ivirico explains and underscores the key differences with the production of exosomes from other cellular therapies.
|
|
|
|
|
|
Purolite, An Ecolab Company
|
|
|
|
|
Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.
|
|
|
Connect With Bioprocess Online:
|
|
|
|
|
|
|
|